About Genechem
Genechem is a company based in Shanghai (China) founded in 2002. Genechem has raised $56.35 million across 2 funding rounds from investors including Humanwell Healthcare, Chuangyuan InnoSpring and Free Trade Zone Fund. Genechem operates in a competitive market with competitors including Arbor Biotechnologies, Singleron, Novogene Corporation, Octant and Rejuvenate Bio, among others.
- Headquarter Shanghai, China
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$56.35 M (USD)
in 2 rounds
-
Latest Funding Round
$56.35 M (USD), Series C
Apr 02, 2020
-
Investors
Humanwell Healthcare
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Genechem
Genechem has successfully raised a total of $56.35M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $56.35 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genechem
Genechem has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Humanwell Healthcare, Chuangyuan InnoSpring and Free Trade Zone Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity & venture capital firm
|
Locked | Locked | Locked | |
|
Principle Capital is engaged in strategic investments and equity partnerships.
|
Locked | Locked | Locked | |
|
Laboratory and blood bank equipment are manufactured for clinical use.
|
Locked | Locked | Locked |
Investor details for Genechem
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genechem
Investment portfolio details for Genechem
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genechem
Detailed financials for Genechem
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genechem Comparisons
Peer comparison for Genechem
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genechem
Genechem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Arbor Biotechnologies, Singleron, Novogene Corporation, Octant and Rejuvenate Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic technologies and drug discovery platforms are provided.
|
|
| Locked | Locked | Locked |
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Human cell interaction platform is provided for drug discovery.
|
|
| Locked | Locked | Locked |
Gene-editing platform and anti-aging therapy for dogs are developed.
|
|
| Locked | Locked | Locked |
Multiple genomic services are provided for analysis and diagnostics.
|
Detailed competitors of Genechem
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genechem
Complete news archive for Genechem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genechem
Genechem was founded in 2002 and raised its 1st funding round 17 years after it was founded.
Genechem is headquartered in Shanghai, China.
Genechem is a funded company, having raised a total of $56.35M across 2 funding rounds to date.
Genechem was established in 2002 in Shanghai, China, within the biotechnology sector focused on molecular biology. A range of gene delivery tools is produced, including lentiviral vectors for knockdown and overexpression, adenoviral systems, adeno-associated viral constructs, and plasmid libraries such as shRNA-SET and CRISPR-Pool. Genomics services are provided alongside custom animal model development for research applications.
Genechem's top competitors include Arbor Biotechnologies, Novogene Corporation and Singleron.
Genechem has 4 investors. Key investors include Humanwell Healthcare, Chuangyuan InnoSpring, Free Trade Zone Fund, and Principle Capital.